Psoriasis Clinical Trials

Showing 801-820 of 888 trials

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

NCT01265823

W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional systemic psoriasis treatment or who are candidates for systemic therapy.

Psoriasis

AbbVie (prior sponsor, Abbott)150 participantsStarted Oct 2010

Circuito Comercial Satelite, Mexico • Iztapalapa, Mexico • Mexico City, Mexico +5 more locations

COMPLETEDPhase 2

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

NCT01465282

The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.

Psoriasis Vulgaris

Creabilis SA160 participantsStarted Dec 2011

Hotsprings, Arkansas, United States • San Ramon, California, United States • Bay City, Michigan, United States +10 more locations

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Related Searches

Cell Responses to IFN-gamma

Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis

EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Open Label Continuation Study in Moderate to Severe Psoriasis

Nicotinamide in the Treatment of Psoriasis

A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Web-based Support to Manage Arthritis Pain

Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care

An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis

Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.

Randomized Study of PH-10 for Psoriasis

Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis